47 results about "Plasmacytoid dendritic cell" patented technology

Tolerogenic populations of dendritic cells are provided, where the dendritic cells are characterized by expression of select tissue-specific homing receptors including the chemokine receptors CCR9; or CMKLR1; or the integrin CD103. The dendritic cells may be conventional / myeloid or plasmacytoid dendritic cells. The cells may be isolated from lymphoid tissue, from blood, or from in vitro culture, e.g. bone marrow culture, etc. Methods are provided for their identification, isolation and targeting in immunotherapeutic interventions in suppressing inflammatory disorders including autoimmunity, transplantation responses and allergic diseases. In some embodiments dendritic cell populations are fixed to render them immunosuppressive, thus allowing the cells to be typed and banked for future use.

A combination which comprises an effective amount of Her2 / Neu antagonist and an effective amount of immunotherapeutic that is capable of activating a human plasmacytoid dendritic cell, myeloid dendritic cell, NK cell, or a combination thereof is disclosed.

The present invention provides an ex vivo method of treating plasmacytoid dendritic cells (pDC) in Th2- or Th17-associated diseases by modulating the cytokine expression or secretion using interferon lambda (IFN-λ). For the Th-2 or Th17-associated diseases, pDC cells from a patient having the disease are exposed ex vivo with IFN-λ in an effective amount to inhibit cytokine releases. The IFN-λ exposed pDC are administered back into the patient. The present invention also provides a method of ex vivo IFN-λ treatment of pDC, in conjunction with co-administration of a composition comprising IFN-λ.

Method for identifying myeloid or plasmacytoid dendritic cells provided by a mammal, stimulated or unstimulated, comprising the steps of: a) preparing a cell sample; b) contracting the cell sample myeloid or plasmacytoid dendritic cells to form a complex; c) detecting the complex; characterized in that the phosphatase is the Receptor type Tyrosine Phosphatase Gamma Protein (PTPRG), acting as a specific marker of said dendritic cells, and in that the compound is a polypeptide capable of selectively bind to the PTPRG or to a fragment thereof or to a oligonucleotide complementary to a PTPRG mRNA logonucleotide in such a manner as to allow the selective recognizing of the dendritic cells in the cell sample.

The invention discloses a tumor microenvironment component marker combination and system for predicting nasopharyngeal carcinoma prognosis. The tumor microenvironment component marker combination comprises a cell cycle proliferation component and at least one of five immune cell components including macrophages, plasmacytoid dendritic cells, CLEC9A + dendritic cells, natural killer cells and plasma cells. According to some examples of the invention, the expression levels of different components in a nasopharyngeal carcinoma tumor microenvironment can be predicted by calculating the expressionlevels of respective feature genes of one tumor cell component and five immunocyte components, and clinical prognosis prediction can be performed on a nasopharyngeal carcinoma patient, so that individualized treatment is facilitated, and finally, survival benefits are brought to the patient.

The present disclosure provides a method for treating lupus, Sjörgen's syndrome or scleroderma, the method comprising administering to the mammal an immunoglobulin which binds an interleukin 3 receptor α (IL-3Rα) chain and which depletes or at least partly eliminates plasmacytoid dendritic cells (p DCs) and basophils to which it binds.

Oligonucleotides containing the non-palindromic sequence motif: X1X2X3X4X5X6X7X8, wherein X1 is C,T,G or A (preferably T or C); wherein X2 is C,T,G or A; wherein X7 is C,T,G or A (preferably G); at least three, and preferably all, of X3, X4, X5, X6 and X8 are T; and with the proviso that, in the motif, a C does not precede a G (in other terms, the nucleic acid motif does not consist of a CpG oligonucleotide), that modulate the immune response of animals of the order Primate, including humans, are disclosed. This immune modulation is characterized by stimulation of proliferation, differentiation, cytokine production and antibody production on B-cells and cell differentiation on plasmacytoid dendritic cells.

This invention discloses an unexpected discovery that plasmacytoid dendritic cells (pDCs) may be segregated into immunogenic or tolerogenic species based on novel biomarkers discovered herein. Exemplary biomarkers include CD8α+β+, CD8α+β−, CD8α−β−, C1q, and IL-9R. For example, pDCs with CD8α+β+, CD8α+β− are tolerogenic and CD8α−β− is immunogenic. Also disclosed are isolated pDCs, compositions comprising the pDCs, methods for isolating the pDCs, methods for treating immune-hyper-reactivity, such as airway hyper-reactivity, food allergy, asthma, and autoimmune disorders, by using compositions containing tolerogenic antigen presenting cells, preferably pDCs disclosed herein. Also disclosed are methods for identifying tolerogenic antigen presenting cells by using one or more novel biomarkers disclosed herein, including RALDH expression, CD8α, CD8βC1qa, C1qc, and IL-9R. Also disclosed are methods for inducing Treg cells by using the pDCs disclosed herein.

Methods and compositions for treating disease are provided. More particularly, methods and compositions of inhibiting pathogenic interferon production are prevented, which may be useful in the treatment of various diseases. In other embodiments, therapeutic compounds and methods for the treatment of autoimmune diseases and chronic inflammatory diseases and / or cancer are provided. One such method is a method for inhibiting pathogenic interferon production or inhibiting activation of plasmacytoid dendritic cells or treating an autoimmune or chronic inflammatory disease, which comprises inhibiting one or more of LL-37 and hCAP18.

The invention relates to PEGylated CpG oligonucleotide and application of the PEGylated CpG oligonucleotide in the preparation of a medicament for improving the IL-12 expression quantity in serum, a medicament for inducing the immunogenicity to an endogenous antigen such as a tumor antigen and a medicament for stimulating the immunocompetence of B cells, plasmacytoid dendritic cells, myeloid dendritic cells, macrophages and peripheral mononuclear cells in the field of vaccine and tumor immunotherapy administration systems. The PEGylated CpG oligonucleotide has the effects of homeostasis improvement and immunoregulation, and response to persistent antigens in vivo can be improved.

The diagnostic markers that provide novel diagnostic criteria to blastic plasmacytoid dendritic cell neoplasm (BPDCN) has been searched, and the presence of immunoblastoid cytomorphology, 8q24 rearrangement, and MYC expression were established as novel markers for subtyping BPDCN. It has been further found that the inhibitors which directly or indirectly inhibit the expression, functions, or signaling pathways of MYC, such as BET bromodomain-selective inhibitors or aurora kinase inhibitors, are effective in MYC-positive BPDCN, and HDAC inhibitors or BCL2 family protein inhibitors are effective as therapeutic drugs for BPDCN.

Dendritic cells play a critical role in antigen-specific immune responses. Materials and methods are provided for treating disease states, including cancer, infectious diseases, autoimmune diseases, transplantation, and allergy by facilitating or inhibiting the migration or activation of a specific subset of antigen-presenting dendritic cells known as plasmacytoid dendritic cells (pDC). In particular, methods for treating disease states are provided comprising administration of chemokine receptor agonists and antagonists, alone or in combination with a disease-associated antigen, with or without an activating agent.

The discovery of plasmacytoid dendritic cell precursors (PDC) as crucial effector cells with high production of type I interferons (IFNs) in early psoriasis development has led to the present invention that blocking of type I IFNs can be used for prevention and therapy of psoriasis. The invention relates to the use of a type I interferon blocking agent, such as a type I IFN antagonist (e.g. an anti-IFN-a antibody) or type I IFN receptor antagonist, for the preparation of a medicament for the prevention and treatment of psoriasis, and to a method of prevention and treatment of psoriasis using a type I interferon blocking agent.

The present disclosure provides a method for treating lupus, Sjogren's syndrome or scleroderma, the method comprising administering to the mammal an immunoglobulin which binds an interleukin 3 receptor alpha (IL-3R alpha) chain and which depletes or at least partly eliminates plasmacytoid dendritic cells (p DCs) and basophils to which it binds.

An object of the present invention is to provide a compound useful as a therapeutic or prophylactic drug for a disease involving the immune system, by suppressing a function of immune cells by suppressing proliferation of activated T cells or suppressing production of interferon alpha (IFN-α) by activated plasmacytoid dendritic cells (pDC), particularly an autoimmune disease such as systemic lupus erythematosus (SLE) and lupus nephritis in SLE patients. The present invention provides a compound represented by general formula (I): [wherein X, R1, R2, R3, R4, R5 and R6 are as described in the description], or a pharmaceutically acceptable salt thereof.

The invention discloses a method for stimulating cartilage tissue differentiation of mesenchymal stem cells, which comprises the following steps: 1) adding dendritic cells separated and cultured in vitro into TGF-beta3 and IFN1 and 2 to obtain plasma cell-like dendritic cells; (2) when the number of the plasma cell-like dendritic cells reaches a certain number, inducing tolerant expression of the plasma cell-like dendritic cells by adopting indoleamine-2, 3-dioxygenase-1, so as to obtain tolerant plasma cell-like dendritic cells; and (3) co-culturing the tolerant plasma cell-like dendritic cells and the mesenchymal stem cells so as to achieve cartilage differentiation of the mesenchymal stem cells. According to the method, the tolerant plasma cell-like dendritic cells are adopted to stimulate the cartilage tissue differentiation of the mesenchymal stem cells, so that the cartilage tissue differentiation period of the mesenchymal stem cells is effectively shortened, the expression efficiency of proteins is also improved, and meanwhile, a solid foundation is laid for treating arthritis and promoting cartilage repair capability.

The present invention refers to a novel combination of nucleotide and cellular vaccine composition and pharmaceutical composition and use thereof for treating and / or preventing diseases, including infectious diseases, cancer, autoimmune diseases, allergy, diabetes and blood disorders. The vaccine composition comprises a nucleotide sequence encoding an antigenic molecule and gene-modified antigen-presenting cells (APCs), preferably provided as an intermixture. The APCs are modified to express immune modulating molecules. Immunization with the vaccine composition of present invention into a subject, induces the host immune system to respond and generate efficient immunity against either pre-existing disease or protect the host against the disease.

It is an object of the present invention to identify a membrane molecule that is specifically expressed on activated plasmacytoid dendritic cells, for the purpose of preventing or improving affection or disease such as cancer, autoimmune disease, allergy, or infectious disease by regulating the functions of dendritic cells capable of integrating an immune system. The present invention provides a protein having any one of the following amino acid sequences:(a) an amino acid sequence as shown in SEQ ID NO: 2;(b) an amino acid sequence, which comprises a deletion, substitution, insertion and / or addition of one or several amino acid residues with respect to the amino acid sequence as shown in SEQ ID NO: 2, and which is capable of regulating the functions of dendritic cells; and(c) an amino acid sequence, which has homology of 80% or more with the amino acid sequence as shown in SEQ ID NO: 2, and which is capable of regulating the functions of dendritic cells.